Foucher N, Pertusa MC, Lahille B, Bernard N, Louis I, Bonarek M, Morlat P, Pometan JP. [Incidence and reasons of premature discontinuation of abacavir: results of a hospital investigation among 628 patients].
Med Mal Infect 2007;
37:684-7. [PMID:
17662547 DOI:
10.1016/j.medmal.2007.05.004]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2007] [Accepted: 05/29/2007] [Indexed: 10/23/2022]
Abstract
OBJECTIVE
The aim of this study was to determine the incidence of abacavir discontinuation within the first two months of treatment and the link with a true hypersensitivity reaction (HSR).
PATIENTS AND METHODS
A retrospective study was made between January 1998 and January 2006 on a cohort of HIV positive patients treated by abacavir delivered by the Bordeaux Saint-André University Hospital pharmacy.
RESULTS
Six hundred (and) twenty-eight patients were included. The reasons for non-renewal of abacavir prescription within the first three months of treatment were investigated. Early discontinuation for adverse effects was reported in 32 patients (5.1%): proved diagnosis of HSR (N=10), uncertain diagnosis of HSR (N=8), and no HSR (N=14). The decision for discontinuation was taken by physician after consultation in 76% of cases.
Collapse